VXRT - Vaxart Corp Forward P/S Multiple

Corporate company logo of Vaxart (VXRT)

The key growth driver for Vaxart, Inc. (VXRT) is the VAAST platform for developing tablet-based vaccines against influenza and norovirus. The forward P/S multiple on this GURU.Markets chart reflects the impact of these developments, with the 1.50 mark capturing this metric. The company's advantages are based on simplified immunization logistics and high production scalability, which significantly reduce costs compared to injections.

VXRT (Vaxart) Market Cap to Projected Revenue history from 07/04/2022 to 07/19/2025

Comprehensive metric breakdowns and analytics for Vaxart Corp (VXRT)

- stock price and consensus target price:
Stock Quotes Vaxart Corp|VXRT - Price Target Chart
- market capitalization statistics:
Market Capitalization Vaxart|VXRT - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Vaxart|VXRT - Accounting Capitalization|Market Capitalization to Book Value Ratio vaxart.com|VXRT - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Vaxart, Inc.|VXRT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Vaxart|VXRT - Company Cumulative Indebtedness|Debt to Book Value Vaxart Inc.|VXRT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Vaxart|Quick Liquidity vaxart.com
- net income and valuation multiples indicators:
VXRT - Company Profit|Projected Future Earnings Vaxart, Inc.|VXRT - Price to Earnings Ratio|Projected Price to Earnings vaxart.com|VXRT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Vaxart, Inc.|VXRT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Vaxart|VXRT - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months vaxart.com|VXRT - Earnings per share increase in current year|Expected earnings per share growth for next year Vaxart, Inc.
- sales and revenue indicators:
VXRT - Company Total Sales|Company Projected Revenue Vaxart Inc.|VXRT - Price-to-Sales Ratio|Forward P/S Multiple Vaxart Inc.
General company analysis:Vaxart (VXRT)
Original product of Vaxart Inc.

The implementation of robotic molecule screening and automated clinical trial data analysis at Vaxart, Inc. (VXRT) is transforming the structure of future revenues, making the company's modeled P/S ratio a key valuation tool. This indicator correlates current market capitalization with projected revenue, allowing investors to promptly identify asset overbought conditions and determine the fair value of the business between quarterly reports.

Key competitors

Forward P/S Multiple GILD (Gilead)|CDTX - Forward Price-to-Revenue Multiple|NVAX - Price-to-Projected Revenue Ratio|CVAC - Forward P/S Multiple|Valneva (VALN) - Price-to-Projected Revenue Ratio|Vir Biotechnology - Forward Price to Sales|SIGA (SIGA Technologies Inc) - Forward P/S Multiple|EBS - Projected Price to Revenue|Forward Price-to-Revenue Multiple AVIR (Atea Pharmaceuticals)|Price-to-Projected Revenue Ratio IVVD (Invivyd Corp)|Forward P/S Multiple ENTA (enanta.com)|Forward Price to Sales INO|HilleVax Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Kalaris Therapeutics Inc KLRS|DYAI: Forward P/S Multiple|NNVC - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple TLPH|Price-to-Projected Revenue Ratio COCP|Price-to-Projected Revenue Ratio Traws Pharma Inc (TRAW)|DWTX (Dogwood Therapeutics) - Forward Price to Sales|Forward P/S Multiple QLGN (Qualigen Therapeutics)|ALVR - Forward Price-to-Revenue Multiple|VBIV - Price-to-Projected Revenue Ratio|VIRI - Forward P/S Multiple